Johnson & Johnson’s coronavirus vaccine is set for vetting by a panel of outside advisers to the US Food and Drug Administration (FDA) on Friday, one of the final steps towards potential authorisation of the country’s first one-dose immunisation against Covid-19.

If the panel votes that the vaccine’s benefits outweigh its risks, as expected, the agency could grant emergency clearance within days, providing a badly needed boost to US vaccine supplies. While the committee’s decision is nonbinding, the FDA usually follows its advisers’ recommendations...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.